Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cascara sagrada laxatives

This article was originally published in The Tan Sheet

Executive Summary

FDA will not defer enforcement action against manufacturers of OTC laxatives containing cascara sagrada, agency states in Sept. 2 letter to Atlanta law firm Arnall Golden Gregory denying citizen petition. Decision barring laxatives containing ingredient from initial entry into interstate commerce as of Nov. 5, 2002 stands, FDA says. Agency reply follows recent letter to AHPA denying association's request to move cascara sagrada from Category III to Category I (1"The Tan Sheet" Aug. 4, 2003, p. 11)...

You may also be interested in...

Aloe, Cascara Sagrada Safety In Laxatives Still Needs Supporting Data – FDA

Data on aloe and cascara sagrada from the German Commission E monographs, World Health Organization reviews and the National Toxicology Program are insufficient to support the safety and efficacy of the ingredients in OTC laxatives, FDA concludes in a July 3 letter to the American Herbal Products Association

Eli Lilly To Explore MiNA's Small Activating RNA Technology

Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.

Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence

The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts